Figure 4. GRHL2-knockdown suppressed growth of CRC primary tumors in a mouse xenograft model. (A) Tumor growth was monitored in BALB/c mice implanted with Scr-con and GRHL2-KD cells. Tumor size was measured every 4 d and tumor volume was calculated as described in the Materials and Methods section. Tumors in the GRHL2-KD groups grew more slowly than those in the Scr-con groups. (B) Representative tumors from the mice of each group are shown. Tumors from the GRHL2-KD groups were smaller than those from the Scr-con groups. (C) As compared with Scr-con controls, the average tumor volumes from mice in the GRHL2-KD groups were markedly smaller. (D)The average weight of primary tumors originating from GRHL2-KD cells was lower than those from Scr-con cells. (E) Western blot was performed to confirm the downregulation of GRHL2 expression in tumors from GRHL2-KD mice. Samples were selected and paired randomly. Data were expressed as mean ± SD *indicates P < 0.05, **indicates P < 0.01.